The Priority Review

Tag

Pediatric

1 story

  1. Clinical trials

    Janssen posts Phase 3 ustekinumab results in pediatric ulcerative colitis

    Janssen Research & Development, LLC posted results of a Phase 3 ustekinumab study in 112 participants with moderately to severely active ulcerative colitis. The record lists 25 percent in clinical remission at induction Week 8.